Angina Pectoris Drugs - Global Market Outlook (2017-2023)

According to Stratistics MRC, the Global Angina Pectoris Drugs Market is accounted for $8501.3 million in 2016 and expected to grow at a CAGR of 6.7% to reach $13441.0 million by 2023. The market factors such as sedentary lifestyle and obesity in young generation, research and developments for effective drugs, high demand for target specific and tailored drugs for angina pectoris treatment and in developing countries the awareness related to cardiovascular diseases is increasing which in turn is driving market growth. Further market will witness few trends such as introduction of new pharmacologic agents, Genomic medicines and growing trend of strategic alliances and acquisitions.
β-Adrenoceptor antagonists (β-blockers) are recommended for the first-line treatment of heart failure, coronary artery disease, and atrial fibrillation as well as of hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. β-Blocker therapy should also be considered in asymptomatic patients with large areas of ischemia (level IIa C evidence) and in microvascular angina to improve effort-related angina symptoms. According to The British journal of Cardiology, chronic stable angina pectoris affects around 2 – 4% of the population in western countries and it is associated with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1–2% and 3% respectively.

Current European and North American guidelines advise continuing dual antiplatelet therapy for 1 year following an acute coronary syndrome. Cangrelor is a novel P2Y12 inhibitor that, like ticagrelor, binds directly to the receptor and induces reversible blockade. The drug is a nonthienopyridine adenosine triphosphate analogue that is administered intravenously and has shown promising results in clinical trials to date. bciximab (a monoclonal antibody fragment), tirofiban (a small, non-peptide molecule) and eptifibatide (a cyclic heptapeptide derived from rattlesnake venom) are used in clinical practice.
There are three main classes of L-type channel blockers: phenylalkyamines, benzothiazapines, and 1,4-dihydropyridines. In particular, CCBs have been one of the most widely used classes of antihypertensive agents in the last 20 years, based on their effectiveness in reducing BP levels, good tolerability, and abundant evidence on reducing cardiovascular and renal consequences of hypertension. In the United States, eight of the major CCBs are currently marketed. From a clinical point of view, dihydropyridinic CCBs are considered one of the first-line therapeutic options to treat hypertension and reduce hypertension-related cardiovascular morbidity and mortality. Dihydropyridine calcium channel blockers are available in single pill combinations with betablocker or angiotensin receptor blocker; verapamil is available in combination with an ACE inhibitor.
North America is projected to dominate this market due to higher prevalence of chronic diseases and better healthcare infrastructure. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. Europe is the second largest market followed by Asia Pacific. Asia Pacific is estimated to grow at significantly due to rising prevalence of angina pectoris, high awareness related to cardiovascular diseases and developing healthcare infrastructure.
The key players in global Angina Pectoris Drugs market are Astellas Pharma, Cardium Therapeutics, Cardeus Pharmaceuticals, CardioVascular BioTherapeutics (CVBT), Ark Therapeutics Group plc, HUYA Bioscience International LLC, Bristol-Myers Squibb Company, Korea Otsuka Pharmaceutical Co.,Ltd, Pfizer, Inc., Baxalta US Inc., Sanofi SA, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca PLC and TSH Biopharm Corporation Limited.

Drug Classes Covered:
• Angiotensin-converting enzyme inhibitors
• Beta-adrenergic blocking agents
• Calcium channel blockers
• Short & Long – acting Nitroglycerines
• Anti-ischemic agents
• Antiplatelet agents

End Users Covered:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements